Asahi Kasei Bags Japan Commercial Rights for Two Sobi Treatments

September 16, 2022
Asahi Kasei Pharma said on September 15 that it has acquired the exclusive distribution rights in Japan for two products developed by Swedish Orphan Biovitrum (Sobi). The financial terms of the agreement were not disclosed. The two products subject to...read more